Table 2. Unadjusted and Propensity-Adjusted 2-Year Outcomes for 282 Neonates With Acute Symptomatic Seizures.
| Variable | ASM, median (IQR) | Unadjusted (95% CI) | Unadjusted P value | Adjusted (90% CI) | Adjusted P value | |
|---|---|---|---|---|---|---|
| Discontinued (n = 106) | Maintained (n = 176) | |||||
| WIDEA-FS | ||||||
| 12 moa | 114 (98 to 127) | 112 (94 to 124) | Difference, 5 (−1 to 11) | .13 | Difference, 1 (−4 to 7) | .70 |
| 18 mob | 149 (126 to 160) | 144 (118 to 157) | Difference, 7 (0 to 14) | .04 | Difference, 4 (−2 to 10) | .31 |
| 24 moc | 165 (150 to 175) | 161 (129 to 174) | Difference, 7 (−1 to 15) | .09 | Difference, 4 (−3 to 11) | .40 |
| Postneonatal epilepsy, No. (%) | 12 (11) | 25 (14) | OR, 0.8 (0.4 to 1.6) | .49 | OR, 1.5 (0.7 to 3.4) | .32 |
| Motor impairment (GMFCS ≥II), No. (%) | 13 (13) | 32 (19) | OR, 0.6 (0.3 to 1.3) | .18 | OR, 0.9 (0.4 to 1.9) | .71 |
Abbreviations: ASM, antiseizure medication; GMFCS, Gross Motor Function Classification System; IQR, interquartile range; OR, odds ratio; WIDEA-FS, Warner Initial Developmental Evaluation of Adaptive and Functional Skills.
a
n = 187 at 12 months.
b
n = 220 at 18 months.
c
n = 270 at 24 months.